NCT02140164View on ClinicalTrials.gov

Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

June 30, 2016

Conditions
Retinitis Pigmentosa
Interventions
DRUG

Minocycline

Oral dose of 100 mg (or appropriate weight-adjusted pediatric dose) of minocycline twice daily for 12 months.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

The Emmes Company, LLC

INDUSTRY

lead

National Eye Institute (NEI)

NIH

NCT02140164 - Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa | Biotech Hunter | Biotech Hunter